^
    1d
    A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Venclexta (venetoclax) • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    4d
    EXCALIBER: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=939, Active, not recruiting, Celgene | Trial primary completion date: Mar 2026 --> Nov 2027
    Trial primary completion date
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    21d
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=258, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    22d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    26d
    Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure (clinicaltrials.gov)
    P1, N=30, Recruiting, Augusta University | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    28d
    Daratumumab in STK11 Mutated NSCLC (clinicaltrials.gov)
    P2, N=8, Completed, NYU Langone Health | Recruiting --> Completed | N=14 --> 8 | Trial completion date: Dec 2026 --> Nov 2025 | Trial primary completion date: May 2026 --> Nov 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    29d
    Rapid dFLC Response Predict CHR in AL Amyloidosis (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Peking University People's Hospital | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex (daratumumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    DARATALL-VHR: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD38 (CD38 Molecule)
    |
    cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    GMMG-DADA: Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, University of Cologne | Recruiting --> Active, not recruiting | N=160 --> 67 | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Dec 2029 --> Mar 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    LINKER-MM8: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P2/3, N=1570, Not yet recruiting, Regeneron Pharmaceuticals
    New P2/3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    2ms
    CT-P44 3.1: A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma (2024-518588-36-00)
    P2/3, N=42, Recruiting, Celltrion Inc.
    New P2/3 trial
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)